Related Experiment Videos

Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines

Thomas Schöndorf1, Christian M Kurbacher, Uwe-Jochen Göhring

  • 1Department of Gynecology and Obstetrics, University of Cologne, Germany. thomas.schoendorf@medizin.uni-koeln.de

Anticancer Research
|August 15, 2002
PubMed
Abstract

Insights

Anticancer drugs can induce mdr1-gene transcription, contributing to multidrug resistance (MDR) and treatment failure in ovarian cancer. This induction varies between patients, highlighting the need for personalized therapy strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anticancer drug resistance is a significant challenge in oncology, particularly in ovarian cancer treatment.
  • The multidrug resistance (MDR) phenotype is often linked to mdr1-gene overexpression.
  • The capacity of common antineoplastics to induce mdr1 has not been fully investigated.

Purpose of the Study:

  • To investigate the mdr1-inducing potential of commonly used anticancer drugs in ovarian cancer cell lines.
  • To explore the role of mdr1-gene induction in secondary treatment failure.

Main Methods:

  • Short-term cultures of 7 ovarian cancer cell lines were exposed to cisplatin, doxorubicin, or paclitaxel.
  • Quantitative real-time RT-PCR was used to detect and quantify mdr1-transcripts.
  • GAPDH mRNA was used for normalization of mdr1-mRNA levels.

Main Results:

  • Mdr1-mRNA was detected in all tested ovarian cancer cell lines.
  • The tested anticancer drugs induced mdr1-transcription in 62% of the assays.
  • No decrease in mdr1-mRNA levels was observed during the experiments.

Conclusions:

  • Antineoplastic drugs can induce mdr1, contributing to ovarian cancer therapy failure.
  • The extent of mdr1-induction by anticancer drugs can differ among individuals.
  • The described method may aid in predicting tumor chemoresistance development.

Related Concept Videos